Barclays PLC Acelrx Pharmaceuticals Inc Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$0.49 - $1.02 $7,114 - $14,810
-14,520 Closed
0 $0
Q3 2021

Nov 09, 2021
BUY
$0.93 - $1.51 $2,796 - $4,540
3,007 Added 26.12%
14,520 $15,000
Q2 2021

Aug 13, 2021
SELL
$1.03 - $1.7 $74,594 - $123,117
-72,422 Reduced 86.28%
11,513 $16,000
Q1 2021

May 13, 2021
BUY
$1.25 - $2.77 $72,625 - $160,937
58,100 Added 224.89%
83,935 $142,000
Q4 2020

Feb 11, 2021
SELL
$1.18 - $1.98 $12,611 - $21,162
-10,688 Reduced 29.26%
25,835 $32,000
Q3 2020

Nov 12, 2020
SELL
$1.01 - $1.81 $39,205 - $70,258
-38,817 Reduced 51.52%
36,523 $52,000
Q2 2020

Aug 12, 2020
BUY
$1.03 - $1.69 $50,839 - $83,416
49,359 Added 189.98%
75,340 $90,000
Q1 2020

May 13, 2020
SELL
$0.76 - $2.07 $40,194 - $109,476
-52,887 Reduced 67.06%
25,981 $30,000
Q4 2019

Feb 10, 2020
BUY
$1.66 - $2.4 $63,694 - $92,088
38,370 Added 94.75%
78,868 $166,000
Q3 2019

Nov 14, 2019
SELL
$2.1 - $2.87 $21,298 - $29,107
-10,142 Reduced 20.03%
40,498 $88,000
Q2 2019

Aug 14, 2019
SELL
$2.1 - $3.93 $259,423 - $485,492
-123,535 Reduced 70.93%
50,640 $128,000
Q1 2019

May 15, 2019
SELL
$2.35 - $3.83 $410,455 - $668,955
-174,662 Reduced 50.07%
174,175 $606,000
Q4 2018

Feb 14, 2019
BUY
$2.13 - $4.8 $743,022 - $1.67 Million
348,837 New
348,837 $805,000
Q3 2018

Nov 14, 2018
SELL
$2.6 - $4.6 $8,840 - $15,639
-3,400 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$2.13 - $4.2 $7,242 - $14,280
3,400 New
3,400 $11,000
Q1 2018

May 15, 2018
SELL
$1.7 - $2.35 $1,536 - $2,124
-904 Closed
0 $0
Q4 2017

Feb 14, 2018
SELL
$1.75 - $5.5 $97,245 - $305,629
-55,569 Reduced 98.4%
904 $2,000
Q3 2017

Nov 14, 2017
BUY
$2.9 - $4.6 $163,771 - $259,775
56,473
56,473 $260,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email